comparemela.com

Latest Breaking News On - Minervax - Page 1 : comparemela.com

MinervaX begins critical GBS vaccine trial

Group B streptococcus vaccine study will involve adult groups with and without underlying conditions - News - PharmaTimes

United kingdomSouth africaPaul heathLidia oostvogelsCentre for vaccinology

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

/PRNewswire/ MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first.

South africaUnited kingdomCity ofLidia oostvogelsIsabel leroux roelsPaul heathCentre for vaccinologyGroupb streptococcusSt george vaccine instituteLund universityLancefield groupb streptococcusMinervax apsChief medical officerPrincipal investigatorOlder adultsVaccine institute

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

/PRNewswire/ MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the.

South africaUnited kingdomLidia oostvogelsGroupb streptococcalDrug administrationBoehringer ingelheimGroupb strep internationalGhent universityGroupb streptococcusLund universityEuropean medicines agencyGroupb strepClinical developmentChief medical officerSenior vice presidentArea head

MinervaX reveals financing to development group B streptococcus vaccine

Plans include phase 3 clinical development of novel GBS vaccine and an efficacy evaluation - News - PharmaTimes

South africaNew zealand generalNew zealandUnited kingdomVeronica gambillaraPureos bioventuresEuropean medicines agencyImpact fundEuropean investment bankTrill impact venturesSanofi venturesSunstone life science venturesWellington partnersAdjuvant capital

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

/PRNewswire/ MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the.

South africaNew zealand generalNew zealandFrance generalUnited kingdomVeronica gambillaraPureos bioventuresChristian thomsenGroupb strep internationalGroupb streptococcusLund universityEuropean unionEuropean medicines agencyGroupb strepImpact fund novo holdingsEuropean investment bank

vimarsana © 2020. All Rights Reserved.